MAaGI Medical's "i" Series Multimodal Tumor Therapy Debuts at APSCVIR 2026, Showcasing 8-Month OS Improvement in Pancreatic Cancer
核心洞察
MAaGI Medical (搜索) globally debuted its "i" Series multimodal tumor therapy platform at the 20th APSCVIR Annual Scientific Meeting in Suzhou, China, from June 11–14, 2026.
The technology alternates cryogenic freezing and radiofrequency heating to convert immune-"cold" tumors into "hot" tumors, with mechanistic findings published on the cover of *Theranostics*.
At ASCO 2026, combining this multimodal therapy with immunotherapy demonstrated an 8-month overall survival improvement in pancreatic cancer (搜索) versus conventional chemotherapy.
At the 20th Annual Scientific Meeting of the Asia Pacific Society of Cardiovascular and Interventional Radiology (APSCVIR 2026), held from June 11 to 14 at the Suzhou International Expo Centre, MAaGI Medical (搜索) unveiled its "i" Series multimodal tumor therapy technology to the global interventional radiology community. The congress, chaired by Academician Gao-Jun Teng of the Chinese Academy of Sciences, convened over one thousand scholars worldwide, and the "i" Series emerged as a central highlight, drawing sustained attention for its integration of precision ablation, immune activation, and digital intelligence.
Converting "Cold Tumors" into "Hot Tumors" Through Thermophysical Immunotherapy
MAaGI Medical (搜索)'s proprietary multimodal tumor therapy platform operates by rapidly alternating between cryogenic freezing and radiofrequency heating, coupled with precise thermal dosage control. This dual mechanism achieves efficient in situ inactivation of tumor cells while disrupting them to release tumor antigens, effectively transforming traditionally immune-"cold" tumors into immune-"hot" tumors responsive to immunotherapy. The technology has already navigated China's special review pathway for innovative medical devices and secured market approval.
Mechanistic validation has been published on the cover of the international journal Theranostics. The research demonstrated that multimodal tumor therapy significantly extends progression-free survival in patients with advanced liver cancer (搜索). Critically, the study identified CX3CR1 (搜索)⁺GPR56 (搜索)⁺ tumor-responsive CD8⁺ T cells as key functional subsets mediating long-lasting antitumor immunity, with the expansion ratio of this cell subset after multimodal treatment showing a significant positive correlation with progression-free survival.
Pancreatic Cancer (搜索) Data Presented at ASCO 2026
At the recently concluded 2026 Annual Meeting of the American Society of Clinical Oncology (ASCO), MAaGI Medical (搜索) presented its latest clinical data in pancreatic cancer (搜索). The results showed that combining multimodal therapy to convert pancreatic tumors from "cold" to "hot" with immunotherapy achieved an 8-month improvement in overall survival compared to conventional chemotherapy. This finding brings new optimism to the treatment of pancreatic cancer, often referred to as the "king of cancer."
The "i" Series: Digital Empowerment for Precision Intelligence
The "i" Series platform represents a significant intelligent upgrade over prior iterations. It constructs a bespoke digital tumor model for each patient, dynamically simulating, forecasting, and steering the spatial distribution of the energy field. Preoperatively, it delivers precise lesion planning via image fusion. Intraoperatively, it captures individualized parameters—including tumor density, perfusion, and impedance—to regulate thermal dosage and monitor the temperature field in real time, ensuring accurate, visualized targeting. Postoperatively, the system provides a holistic forecast and assessment of outcomes.
This data-driven approach allows clinicians to move beyond traditional empirical procedures and deliver "tailored" personalized precision medicine. The platform strives to maximize each patient's long-term systemic anti-tumor immune memory while ensuring standardized, highly controllable procedures.
International Expert Validation
The global launch event featured a distinguished assembly of experts, including Academician Gao-Jun Teng, Professor Jia-Ping Li (President of the Cancer Hospital Affiliated with Guangzhou Medical University), Professor Wen-Tao Li (Director of the Interventional Oncology Department at Fudan University Shanghai Cancer Center), Professor Long Jiao from The Royal Marsden Hospital (UK), Professor Hicham Kobeiter from Henri Mondor University Hospital (France), Professor Shuichiro Shiina from the Sasaki Institute (Japan), and Professor Alex Tang, former President of APSCVIR.
Professor Long Jiao praised the technology for achieving precise local eradication while simultaneously activating the body's anti-tumor immune response through an in-situ vaccine effect, aligning with the principles of personalized precision medicine. Professor Li Wentao noted that the technology can induce anti-tumor immunity in situ, effectively reducing the risk of recurrence and metastasis, and highlighted its breakthrough potential in primary liver cancer (搜索) and pancreatic cancer (搜索) to open a new pathway for interventional immunotherapy.
Academician Gao-Jun Teng, in his keynote report "Interventional Radiology in China: New Horizons," specifically cited MAaGI Medical (搜索)'s multimodal technology as an exemplary innovation reshaping the landscape of precision oncology.
Clinical Implementation and Global Outlook
Supported by the 2025 High-End Medical Equipment Promotion and Application Program of China's Ministry of Industry and Information Technology and the National Health Commission, the technology has been fully implemented across multiple clinical departments—including Interventional Radiology, Hepatobiliary Surgery, Thoracic Surgery, and Oncology—in more than ten leading hospitals throughout China.
Global experts at the congress unanimously agreed that the "i" Series multimodal ablation technology balances locally precise, minimally invasive eradication with systemic immune response, providing an ideal technological platform for interventional immunotherapy of solid tumors. MAaGI Medical (搜索) is positioning this integrated solution as a "China Solution" for minimally invasive oncological interventions, leading the field into what it describes as a new era of interventional immunotherapy for solid tumors.